| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIOMARIN PHARMACEUTICAL | 13 | 12 | +0,46 % | ||
| AVADEL PHARMACEUTICALS | 9 | 6 | -1,09 % | ||
| AMICUS THERAPEUTICS | 8 | 1 | -0,82 % | ||
| CYTOKINETICS | 7 | 1 | -0,93 % | ||
| MIRUM PHARMACEUTICALS | 7 | 1 | +2,26 % | ||
| BIONTECH | 6 | 13 | -0,06 % | ||
| ALTIMMUNE | 6 | - | +0,91 % | ||
| DISC MEDICINE | 5 | 7 | -11,50 % | ||
| GILEAD SCIENCES | 5 | 5 | +0,83 % | ||
| AMGEN | 4 | 27 | +0,59 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06:10 | Cathie Woods ARK Invest setzt Verkäufe bei Ionis Pharma fort | 1 | Investing.com Deutsch | ||
| 03:29 | FDA Approves Cytokinetics' MYQORZO For Treatment Of Obstructive Hypertrophic Cardiomyopathy | 10 | RTTNews | ||
| Fr | Cytokinetics gains FDA approval of aficamten for hypertrophic cardiomyopathy | 1 | Seeking Alpha | ||
| Fr | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | 6 | GlobeNewswire (USA) | ||
| Fr | Stifel reaffirms Buy rating on Disc Medicine stock amid FDA review speculation | 1 | Investing.com | ||
| Fr | Sarepta Therapeutics tauscht Wandelanleihen im Wert von 291,4 Mio. USD um | 6 | Investing.com Deutsch | ||
| Fr | Stifel bestätigt "Buy"-Rating für Disc Medicine trotz Spekulationen um FDA-Prüfung | 1 | Investing.com Deutsch | ||
| Fr | Jefferies reiterates Buy rating on Disc Medicine stock amid FDA concerns | 2 | Investing.com | ||
| Fr | Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Fr | FDA-Zulassung für Herzmedikament MYQORZO beflügelt Cytokinetics-Aktie | 5 | Investing.com Deutsch | ||
| Fr | ROUNDUP/Aktien New York Schluss: Erholung geht weiter | 740 | dpa-AFX | NEW YORK (dpa-AFX) - Die US-Börsen haben sich am Freitag weiter von ihrem jüngsten Rücksetzer erholt. Eine Jahresendrally sei nach wie vor möglich, sagte ein Investmentexperte. Es herrschte unvermindert... ► Artikel lesen | |
| Fr | Jim Cramer Highlights Massive Gains for Terns Pharmaceuticals Shareholders | 1 | Insider Monkey | ||
| Fr | Trump Announces Reduced Drug Pricing Deal With Amgen, Gilead And Other Pharma Firms | 11 | Forbes | ||
| Fr | BioMarin Stock Surges Nearly 20% After $4.8 Bln Amicus Acquisition News | 248 | AFX News | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) shares rose 19.51%, climbing $10.13 to $62.08, after the company announced a definitive agreement to acquire Amicus Therapeutics for... ► Artikel lesen | |
| Fr | Cytokinetics, Incorporated: Cytokinetics Announces FDA Approval of MYQORZO (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms | 6 | GlobeNewswire (USA) | ||
| Fr | BioMarin's Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition | 7 | MedCity News | ||
| Fr | Sarepta Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Fr | Syndax Pharmaceuticals Inc - 8-K, Current Report | 4 | SEC Filings | ||
| Fr | Disc Medicine: BMO bekräftigt "Outperform"-Rating trotz FDA-Prüfungsbedenken | 1 | Investing.com Deutsch | ||
| Fr | Vaxcyte, Inc. - 8-K, Current Report | - | SEC Filings |